MREO Live signaler | Maksimer profitt med Getagraph.com

KJøP 123247 min ago

@ $3.74

Utstedt: 14 feb 2024 @ 18:33

Avkastning: -12.57%

Forrige signal: feb 14 - 17:06

Forrige signal: Selg

Avkastning: 0.00 %

Live Chart Being Loaded With Signals

Commentary (9 mai 2024 @ 22:00):

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally...

Stats
Dagens volum	499 463
Gjennomsnittsvolum	1.17M
Markedsverdi	457.99M
EPS	$0 ( 2024-03-26 )
Neste inntjeningsdato	( $0 ) 2024-05-21
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-16.35
ATR14	$0.00500 (0.15%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-08	Ekblom Anders	Buy	45 000	Share Options (Right to buy)
2024-02-08	Ekblom Anders	Buy	19 471	Deferred Restricted Stock Units
2024-02-08	Jacquet Pierre	Buy	45 000	Share Options (Right to buy)
2024-02-08	Jacquet Pierre	Buy	15 553	Deferred Restricted Stock Units
2024-02-08	Yoskowitz Marc J	Buy	45 000	Share Options (Right to buy)

INSIDER POWER
-60.62
Last 97 transactions
Buy: 2 158 393 \| Sell: 9 188 547

Volum Korrelasjon

Lang: 0.12 (neutral)

Kort: -0.21 (neutral)

Signal:(54.729) Neutral

Mereo BioPharma Group plc Korrelasjon

10 Mest positive korrelasjoner
CFBK	0.888
SLNO	0.887
PBPB	0.885
PROV	0.873
ECOR	0.867
ARDX	0.865
RBKB	0.861
ISTR	0.854
CXDO	0.854
CPLP	0.851

10 Mest negative korrelasjoner
OSMT	-0.878
PFBI	-0.858
HCM	-0.847
MLVF	-0.847
IQ	-0.844
RMRM	-0.843
BFRI	-0.838
COCO	-0.833

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Mereo BioPharma Group plc Korrelasjon - Valuta/Råvare

-0.37
( neutral )

-0.29
( neutral )

0.00
( neutral )

0.55
( weak )

0.50
( neutral )

Mereo BioPharma Group plc Økonomi

Annual	2023
Omsetning:	$10.00M
Bruttogevinst:	$7.43M (74.26 %)
EPS:	$0

FY	2023
Omsetning:	$10.00M
Bruttogevinst:	$7.43M (74.26 %)
EPS:	$0

FY	2022
Omsetning:	$1.51M
Bruttogevinst:	$571 000 (37.89 %)
EPS:	$-0.280

FY	2021
Omsetning:	$36.46M
Bruttogevinst:	$18.56M (50.89 %)
EPS:	$0.159

Financial Reports:

No articles found.

Mereo BioPharma Group plc

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.